StockNews.com Upgrades Can-Fite BioPharma (NYSE:CANF) to “Hold”

Can-Fite BioPharma (NYSE:CANF) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Several other equities analysts have also weighed in on CANF. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

CANF stock traded down $0.06 during midday trading on Thursday, reaching $1.53. The stock had a trading volume of 884,280 shares, compared to its average volume of 148,379. The firm has a fifty day simple moving average of $2.19 and a two-hundred day simple moving average of $2.51. The stock has a market cap of $5.42 million, a PE ratio of -0.85 and a beta of 1.32. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.